Abstract

Measles virus (MV) is a negative strand RNA virus of the family Paramyxoviridae, and the attenuated Edmonston-B strain can be engineered by the reverse genetics system. Here we constructed the recombinant Edmonston strain of measles virus (MV-Ed) that expressed hepatitis C virus (HCV) envelope proteins (rMV-E1E2). The rMV-E1E2 successfully expressed HCV E1 and E2 proteins. To evaluate its immunogenicity, NOD/Scid/Jak3null mice that were engrafted with human peripheral blood mononuclear cells (huPBMC-NOJ) were infected with this rMV-E1E2. Although human lymphocytes could be isolated from the spleens of mock-infected mice during the 2-weeks-long experiment, the proportion of mice that were infected with MV or rMV-E1E2 was decreased in a viral dose-dependent manner. Over 103 PFU of virus infection decreased the human PBL to less than 5%. Significant decrease of B cell population in human PBL from rMV-E1E2 infected NOD-SCID mice and decrease of T cell population in those from MV infected mice were observed. Human antibody production in these mice was also examined. Thus, the results in this study may contribute for future improvement of recombinant vaccine using measles virus vector.

Highlights

  • Measles virus (MV) is classified into the family Paramyxoviridae

  • The results in this study revealed that more than PFU of MV or PFU of rMV-E1E2 infection decreased the human PBL to less than 5%

  • We detected a significant amount of MV-specific antibodies in the rMV-E1E2-infected mice (n = 3)

Read more

Summary

Introduction

Measles virus (MV) is classified into the family Paramyxoviridae. Its genome is composed of 15,894 nucleotides, which encodes a nucleocapside protein (N), phospho protein (P), matrix (M), haemaglutinin (H), fusion (F), and viral polymerase (L). The establishment of the reverse genetic system for the rescue of an attenuated Edmonston-B stain from cloned DNA [1] enabled to develop measles virus as virus expression vector. The MV vaccine is a well-known, live-attenuated vaccine and has proven to be one of the safest, most stable, and effective human vaccines [8]. This vaccine is produced on a large scale in many countries and used at low cost through the Extended Program on Immunisation of the WHO [9,10]. MV possesses a high potential for the vaccine vector

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.